Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Lumykras“
Suchtreffer
Begriffe & Kennungen
Lumykras
Eintrag öffnenLumykras · 4.1 Therapeutic indications · 1
Eintrag öffnenLumykras · 4.3 Contraindications · 1
Eintrag öffnenLumykras · 4.3 · Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Eintrag öffnenLumykras · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenLumykras · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenLumykras · 4.5 · 6 an acidic beverage (non-diet cola) decreased sotorasib Cmax by 32% and AUC by 23%. The clinical relevance of
Eintrag öffnenLumykras · 4.5 · 7 Effect of sotorasib on P-gp substrates Co-administration of sotorasib with digoxin (a P-glycoprotein [P-gp]
Eintrag öffnenLumykras · 4.5 · Acid-reducing agents Co-administration of sotorasib with a PPI (omeprazole) or an H2 receptor antagonist (famo
Eintrag öffnenLumykras · 4.5 · Avoid co-administration of LUMYKRAS with CYP3A4 substrates with narrow therapeutic indices, including but not
Eintrag öffnenLumykras · 4.5 · BCRP substrates LUMYKRAS is a weak BCRP inhibitor. Co-administration of LUMYKRAS with a BCRP substrate led to
Eintrag öffnenLumykras · 4.5 · CYP2B6, CYP2C8, CYP2C9 and CYP2C19 substrates In vitro data indicated that sotorasib may have the potential to
Eintrag öffnenLumykras · 4.5 · CYP2D6 substrates In vitro data indicated that sotorasib may have the potential to inhibit CYP2D6, the clinica
Eintrag öffnenLumykras · 4.5 · CYP3A4 inhibitors Co-administration of multiple dose itraconazole (a strong CYP3A4 and P-gp inhibitor) did not
Eintrag öffnenLumykras · 4.5 · CYP3A4 substrates Sotorasib is a moderate CYP3A4 inducer. Co-administration of sotorasib with CYP3A4 substrate
Eintrag öffnenLumykras · 4.5 · Co-administration of LUMYKRAS with rosuvastatin (a BCRP substrate) increased the rosuvastatin Cmax by 70% and
Eintrag öffnenLumykras · 4.5 · Co-administration of sotorasib with midazolam (a sensitive CYP3A4 substrate) decreased midazolam Cmax by 48% a
Eintrag öffnenLumykras · 4.5 · Effect of sotorasib on other medicinal products
Eintrag öffnenLumykras · 4.5 · Effects of other medicinal products on sotorasib
Eintrag öffnenLumykras · 4.5 · If co-administration of LUMYKRAS with an acid-reducing agent (such as a PPI or an H2 receptor antagonist) is r
Eintrag öffnen